SPRY ARS Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: SPRY

Price (delayed)

$9.75

Market cap

$940.89M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.57

Enterprise value

$870.19M

Silverback Therapeutics, Inc. operates as a biotechnology company. The Company discovers and develops novel and proprietary ImmunoTAC technology, which is designed to create potent therapeutic molecules that can be systemically ...

Highlights
ARS Pharmaceuticals's quick ratio has soared by 90% YoY
ARS Pharmaceuticals's debt has decreased by 43% YoY and by 16% from the previous quarter
The net income has shrunk by 57% YoY but it has increased by 12% QoQ
SPRY's gross profit has dropped by 98% year-on-year
SPRY's revenue has dropped by 98% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://silverbacktx.com
Peers: OMER OMGA

Key stats

What are the main financial stats of SPRY
Market
Shares outstanding
96.5M
Market cap
$940.89M
Enterprise value
$870.19M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.06
Price to sales (P/S)
30,944.98
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
29,006.44
Earnings
Revenue
$30,000
EBIT
-$54.37M
EBITDA
-$54.29M
Free cash flow
-$59.44M
Per share
EPS
-$0.57
Free cash flow per share
-$0.62
Book value per share
$2.4
Revenue per share
$0
TBVPS
$2.45
Balance sheet
Total assets
$233.19M
Total liabilities
$2.43M
Debt
$274,000
Equity
$230.76M
Working capital
$229.34M
Liquidity
Debt to equity
0
Current ratio
96.92
Quick ratio
95.51
Net debt/EBITDA
1.3
Margins
EBITDA margin
-180,973.3%
Gross margin
100%
Net margin
-181,216.7%
Operating margin
-225,066.7%
Efficiency
Return on assets
-21.5%
Return on equity
-22.2%
Return on invested capital
-33.9%
Return on capital employed
-23.6%
Return on sales
-181,216.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SPRY stock price

How has the ARS Pharmaceuticals stock price performed over time
Intraday
3.07%
1 week
16.77%
1 month
3.72%
1 year
47.73%
YTD
77.92%
QTD
-4.6%

Financial performance

How have ARS Pharmaceuticals's revenue and profit performed over time
Revenue
$30,000
Gross profit
$30,000
Operating income
-$67.52M
Net income
-$54.37M
Gross margin
100%
Net margin
-181,216.7%
SPRY's gross profit has dropped by 98% year-on-year
SPRY's revenue has dropped by 98% year-on-year
The company's operating income has shrunk by 90% YoY but it rose by 7% QoQ
The net income has shrunk by 57% YoY but it has increased by 12% QoQ

Growth

What is ARS Pharmaceuticals's growth rate over time

Valuation

What is ARS Pharmaceuticals stock price valuation
SPRY P/E details
P/E
N/A
P/B
4.06
P/S
30,944.98
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
29,006.44
SPRY's EPS is up by 34% year-on-year and by 20% since the previous quarter
The price to book (P/B) is 85% higher than the last 4 quarters average of 2.2
ARS Pharmaceuticals's equity has decreased by 15% YoY and by 2.7% from the previous quarter
SPRY's revenue has dropped by 98% year-on-year

Efficiency

How efficient is ARS Pharmaceuticals business performance
The company's return on assets has shrunk by 79% YoY but it rose by 8% QoQ
SPRY's ROE has plunged by 78% YoY but it is up by 8% from the previous quarter
SPRY's return on invested capital is up by 35% year-on-year and by 25% since the previous quarter
SPRY's return on sales is up by 12% since the previous quarter

Dividends

What is SPRY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SPRY.

Financial health

How did ARS Pharmaceuticals financials performed over time
ARS Pharmaceuticals's quick ratio has soared by 90% YoY
The company's current ratio has surged by 90% YoY
ARS Pharmaceuticals's debt is 100% less than its equity
ARS Pharmaceuticals's debt has decreased by 43% YoY and by 16% from the previous quarter
ARS Pharmaceuticals's equity has decreased by 15% YoY and by 2.7% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.